ReviewCancers2022
Advances in Cutaneous Squamous Cell Carcinoma Management.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 41 citations in OpenAlex.
- KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma.Molecular therapy. Oncology · 2026Article
- Beyond Binary Positivity: Spectrum of Nodal Tumor Burden in Sentinel Lymph Node Biopsy for High-Risk Cutaneous Squamous Cell Carcinoma.Dermatopathology (Basel, Switzerland) · 2026Article
- Review
- A Treatment Decision Model for Cutaneous Squamous Cell Carcinoma Based on Bayesian Networks.Cancers · 2026Article
- Molecular Hydrogen Attenuates Chronic Inflammation and Delays the Onset of Ultraviolet B-Induced Skin Carcinogenesis in Mice.International journal of molecular sciences · 2026Article
- Advances in Targeted and Immunotherapy for High-Risk Cutaneous Malignancies.Oncology research · 2026Review
- Targeting VISTA as a novel immunotherapy for skin cancer.Frontiers in immunology · 2026Review
- Review
- Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: A Review of Pathogenesis, Diagnosis and Management.Cancers · 2025Review
- The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.Current treatment options in oncology · 2025Review
- Managing Advanced Squamous Cell Carcinoma: A Guide for the Dermatology Clinician.The Journal of clinical and aesthetic dermatology · 2025Review
- Current and Emerging Insights into the Causes, Immunopathogenesis, and Treatment of Cutaneous Squamous Cell Carcinoma.Cancers · 2025Review
- A population-based study using nomograms to predict overall and cancer-specific survival in HPV-associated CSCC.Cancer science · 2025Article
- Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment.Frontiers in immunology · 2025Review
- Predictive role of peripheral blood indicators in the prognosis of patients with cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors.American journal of cancer research · 2025Article
- Eph/ephrin-mediated immune modulation: a potential therapeutic target.Frontiers in immunology · 2025Review
- The Role of Gene Expression Profiling in the Management of Cutaneous Squamous Cell Cancer: A Review.Cancers · 2024Review
- Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers.Dermatopathology (Basel, Switzerland) · 2024Review
- Advances in IL-7 Research on Tumour Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.